Nuveen’s DexCom DXCM Stock Holding History

Nuveen’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-26,800	Closed	-$2K	–	3206
2022 Q3	$2K	Buy	+26,800	New	+$2.27M	﹤0.01%	3256

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nuveen's DXCM Position: Q1 2026 in Review

Nuveen reduced its DexCom (DXCM) stake by 63% in Q1 2026, selling an estimated $202M and leaving 1,724,467 shares worth $108M. The position accounts for 0.03% of the portfolio, ranked #377.

Nuveen first reported a position in DXCM in Q4 2013 and has held it in 47 quarters since. The position peaked at $1.15B in Q3 2021. 958 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Nuveen held 1,724,467 shares of DexCom worth $108M as of Q1 2026.
Nuveen sold 2,907,804 DexCom shares in Q1 2026, an estimated $202M.
DexCom made up 0.03% of Nuveen's portfolio in Q1 2026, its #377 holding.
Nuveen first reported a position in DexCom in Q4 2013 and has held it in 47 quarters since.
Nuveen's DexCom position peaked at $1.15B in Q3 2021.
958 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.